AbbVie Inc (ABBV)vsAxonics Modulation Technologies Inc (AXNX)
ABBV
AbbVie Inc
$289.15
+2.26%
HEALTHCARE · Cap: $504.37B
AXNX
Axonics Modulation Technologies Inc
$0.43
-12.47%
HEALTHCARE · Cap: $3.63B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 14808% more annual revenue ($64.39B vs $431.90M). ABBV leads profitability with a 9.8% profit margin vs -1.3%. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
AXNX
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-85.3%
Fair Value
$152.52
Current Price
$289.15
$136.63 premium
Intrinsic value data unavailable for AXNX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
Earnings expanding 845.0% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Revenue surging 24.8% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Negative free cash flow — burning cash
Currently unprofitable
Operating margin of -2.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.54 suggests the stock is reasonably priced for its growth.
Bull Case : AXNX
The strongest argument for AXNX centers on Price/Book, EPS Growth, Debt/Equity. Revenue growth of 24.8% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 80.6x leaves little room for execution misses.
Bear Case : AXNX
The primary concerns for AXNX are Free Cash Flow, Profit Margin, Operating Margin.
Key Dynamics to Monitor
ABBV profiles as a value stock while AXNX is a growth play — different risk/reward profiles.
AXNX carries more volatility with a beta of 0.83 — expect wider price swings.
AXNX is growing revenue faster at 24.8% — sustainability is the question.
ABBV generates stronger free cash flow (3.1B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 36/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Axonics Modulation Technologies Inc
HEALTHCARE · MEDICAL DEVICES · USA
Axonics, Inc., a medical technology company, is dedicated to the development and commercialization of sacral neuromodulation (SNM) systems. The company is headquartered in Irvine, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?